SeqOne

SeqOne Genomics, headquartered in Montpellier, France, is a rapidly growing deep-tech company that aims to revolutionize personalized medicine through genomic data analysis. Established in 2017, the company's clinical genomic analysis platform, powered by explainable AI, focuses on delivering accurate, user-friendly, and automated solutions across lab technologies in the fields of oncology, rare diseases, and inherited diseases. By simplifying intricate multi-omics analysis workflows, SeqOne paves the way for a future where genetic testing is as routine as traditional blood work, significantly improving health outcomes. The company has garnered recognition, winning awards such as the iLab award and ARC Cancer Foundation’s Hélène Stark prize, and being twice nominated for the esteemed Prix Galien award. Notably, the latest achievement for SeqOne is the €20.00M Series A investment led by Omnes Capital, Elaia, Mérieux Equity Partners, Software Club, IRDI in January 2022. With a focus on Analytics, Big Data, Biotechnology, and Health Care, SeqOne Genomics is well-positioned to make a significant impact in the healthcare industry.